KRAS and non-small cell lung carcinoma: It offers a reason to interpret the highest frequency of TP53 co-mutation in KRAS-driven NSCLC, occurring in approximately 50% of KRAS G12C-mutated tumors, a rate comparable to non-G12C KRAS and non-KRAS subtypes.4